Pioglitazone inhibits mouse liver regeneration induced by partial hepatectomy

Abstract

Abstract: AIM: To investigate the effects of pioglitazone on mouse liver regeneration induced by partial hepatectomy.METHODS: 2/3 partial hepatectomy was performed in C57BL/6J mice. The experimental group mice were treated with pioglitazone (20 mg·kg^-1·d^-1) by oral gavage. The control group mice were treated with vehicle. Mouse serum and liver tissue harvest were performed at serials time point post operation. The liver/body weight ratio were calculated; liver histology was assessed by H&E staining; serum transaminase and glucose were determined by biochemistry assay. Hepatocellular proliferation was eveluated by IHC staining of Ki67 and PH3.RESULTS: There were no hepatic toxic and side effects caused by pioglitazone under the given dosage. Pioglitazone didn't impair the metabolism of serum glucose. The liver growth and hepatocyte proliferation were delayed and inhibited in pioglitazone treated mice in comparison to that in control mice(P＜0.05).CONCLUSION: Pioglitazone inhibits liver regeneration following partial hepatectomy in mice.

Key words: Pioglitazone, Liver regeneration, Partial hapatectomy

CLC Number:

R965.2

CHENG Zhang-jun, YANG Ping-hua, ZHOU Jia-hua, SHEN Feng. Pioglitazone inhibits mouse liver regeneration induced by partial hepatectomy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 851-855.

References

[1] Michalopoulos GK, DeFrances MC. Liver regeneration[J]. Science,1997, 276(5309): 60-66.
[2] Mitchell C, Willenbring H. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice[J]. Nat Protoc, 2008, 3(7): 1167-1170.
[3] Doerr RJ, Castillo MH, Luchette FA, et al. Partial hepatectomy in the mouse[J]. Clin Anat, 1990, 3(4): 279-286.
[4] Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer[J]. Cancer Res, 2000, 60(4): 1129-1138.
[5] Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice[J]. Proc Natl Acad Sci USA, 1998, 95(15): 8806-8811.
[6] Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma[J]. Mol Cell, 1998, 1(3): 465-470.
[7] Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer[J]. Proc Natl Acad Sci U S A, 2000, 97(20): 10990-10995.
[8] Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma[J]. Nat Med, 1998, 49(9): 1046-1052.
[9] Turmelle YP, Shikapwashya O, Tu S, et al. Rosiglitazone inhibits mouse liver regeneration[J]. FASEB J, 2006, 209(14): 2609-2611.
[10] Aoyama T, Ikejima K, Kon K, et al. Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice[J]. Hepatology, 2009, 49(5): 1636-1644.
[11] Motomura W, Takahashi N, Nagamine M, et al. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells[J]. Int J Cancer, 2004, 108(1): 41-46.
[12] Toyoda M, Takagi H, Horiguchi N, et al. A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells[J]. Gut, 2002, 50(4): 563-567.
[13] Galli A, Ceni E, Mello T, et al. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin[J]. Hepatology, 2010, 52(2): 493-505.